SLC5A2 and heart failure: SGLT2 inhibitors, such as dapagliflozin, are particularly well-suited for patients with heart failure, given their ability to reduce hospitalizations and cardiovascular mortality through mechanisms such as natriuresis and hemodynamic stabilization.